Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 1996

View Archived Issues

Bronchoselective beta-adrenergic agonists reported by Almirall

New azole antifungal agents described by Zambon

McNeil describes new antipsychotic compounds

New 5-HT1D antagonists from SmithKline Beecham

PDE IV inhibitors/cytokine inhibitors disclosed by Janssen

EGFR tyrosine kinase inhibitors from Ciba-Geigy for hyperproliferative conditions

New endothelin receptor modulators reported by Texas Biotechnology

JT discloses new compounds for Alzheimer's disease and other CNS disorders

New bisphosphonic acid derivatives from Nippon Chemiphar

Schering-Plough continues research into FPTase inhibitors

Eight presentations at the RSNA on EchoGen

Eastern European approval for Zila's oral cancer diagnostic

Beacon Diagnostics launches first product

Zeneca and Rutgers collaborate on apoptosis research

Oral influenza vaccine from Cortecs enters clinic

BMS-Aurora research agreement on screening technology

Promising clinical results reported for C. parvum therapeutic

Shionogi product pipeline in review

Calydon's lead cancer therapeutic progresses toward clinical trials

Vascular Therapeutics licenses Recordati compound

Chugai starts phase I clinical trials with phosphate binder

Alteon amends ACTION II trial

Cholesterol-lowering activity reported for Yamanouchi LTD4 antagonist

Synsorb Pk licensed to major Japanese pharmaceutical company

FDA requests additional data on H. pylori diagnostic

Neurochem/Parke-Davis collaboration on antiamyloid compounds

Forbes Medi-Tech awarded research grant

New therapeutic approach to neurogenerative disorders

Another Barr generic drug cleared by the FDA

NIH offers licenses for invention related to fusin

NIH offers invention for treating and diagnosing HIV infection for licensing

Method of imaging nicotinic acetylcholine receptors offered for licensing

Techniclone explores MAb-based drug delivery technologies

Assay for diagnosing and monitoring kidney disease available for licensing

New nonoxynol-9 formulations tested at University of Kentucky

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...